211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
The Readout Loud
00:00
Biotecnical Bankruptcy
We've never been in this situation before. Just in the last four years, the sector has kicked out nearly 500 companies. So we're just going agout to see this giant domino effect. There are there are so many assets and so many compounds in development. And companies i feel like, at this point are going to have a very, very tough time going from where they are to crossing the finish line.
Transcript
Play full episode
